HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
German Center for Infection Research, partner site Köln-Bonn, Institute of Virology, University of Cologne, Cologne, Germany.
Elena
E
Knops
Infektiologisches Zentrum, Klinikum Osnabrück, Osnabrück, Germany.
Niels
N
Schübel
German Center for Infection Research, partner site Köln-Bonn, Institute of Virology, University of Cologne, Cologne, Germany.
Eva
E
Heger
German Center for Infection Research, partner site Köln-Bonn, Institute of Virology, University of Cologne, Cologne, Germany.
Maria
M
Neumann-Fraune
German Center for Infection Research, partner site Köln-Bonn, Institute of Virology, University of Cologne, Cologne, Germany.
Rolf
R
Kaiser
German Center for Infection Research, partner site Köln-Bonn, Institute of Virology, University of Cologne, Cologne, Germany.
Stephanie
S
Inden
German Center for Infection Research, partner site Saarbrücken, Max Planck Institute for Informatics, Saarbrücken, Germany.
Prabhav
P
Kalaghatgi
German Center for Infection Research, partner site Köln-Bonn, Institute of Virology, University of Cologne, Cologne, Germany. Electronic address: saleta.sierra-aragon@uk-koeln.de.
Saleta
S
Sierra
D015081:2-Naphthylamine; D000813:Anilides / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000627:therapeutic use; D003521:Cyclopropanes; D018450:Disease Progression; D004338:Drug Combinations; D024882:Drug Resistance, Viral / Q000235:genetics*; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011392:Proline / Q000031:analogs & derivatives; D012367:RNA, Viral / Q000235:genetics; D012254:Ribavirin / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D000072230:Sustained Virologic Response; D017211:Treatment Failure; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D014633:Valine; D017361:Viral Nonstructural Proteins / Q000235:genetics; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; D012324:RNA-Dependent RNA Polymerase
D015081:2-Naphthylamine; D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D004338:Drug Combinations; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D011392:Proline; D012367:RNA, Viral; D012254:Ribavirin; D019438:Ritonavir; D013449:Sulfonamides; D014498:Uracil; D014633:Valine; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C586094:ombitasvir; C588260:dasabuvir; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase; C585405:paritaprevir